Bernstein lifted its price target on UnitedHealth Group to $492 from $444 on May 27 and kept an Outperform rating, a move that points to 27% upside potential from the new level. The call came as analysts continued to reset their views on Unh stock after a rough stretch for managed care shares.
The timing matters because investors are still looking for proof that UnitedHealth's recovery in Medicare Advantage will show up in earnings fast enough to justify higher valuations. Bernstein said the higher target reflects an improved adjusted EPS outlook tied to that recovery and to higher target multiples, with projected 16% adjusted EPS CAGR supporting a richer multiple during a cyclical rebound.
Barclays made a similar move a day earlier, raising its price target on UNH to $429 from $373 while keeping an Overweight rating. That firm said the stock moves seen across managed care companies after first-quarter results look durable, and it still favors managed care companies over healthcare facilities. Even so, Barclays also noted that inflation and commercial mix are becoming larger sources of earnings risk for providers, a reminder that the group’s path back is not a straight line.
UnitedHealth runs Optum Health, Optum Insight, Optum Rx and UnitedHealthcare, businesses that give the company broad exposure across care delivery, services and insurance. Bernstein's call fits a wider view that the stock can recover further in a long-term market for safe stocks in 2026, but the question for investors is whether the rebound in Medicare Advantage will translate into earnings quickly enough to support the new valuation. For now, the analysts are betting that the answer is yes, but the market will have to prove it.
